Incyte Announces Positive Data from Phase 2b Trial of Ruxolitinib Cream in Patients with Atopic Dermatitis
Incyte Corporation (Nasdaq:INCY) today announced positive results from its randomized, dose-ranging, vehicle- and active-controlled Phase 2b study evaluating ruxolitinib cream in patients with atopic dermatitis (AD) who are candidates for topical therapy. The study, part of the True-AD clinical trial program, met its primary endpoint, demonstrating that ruxolitinib cream 1.5% administered twice daily (BID) significantly improved Eczema Area and Severity Index (EASI) scores – a measurement of the extent and severity of AD – from baseline versus vehicle control (non-medicated cream) at Week 4. Additionally, treatment with ruxolitinib cream 1.5% BID resulted in a rapid and sustained reduction in itch versus vehicle, a key secondary endpoint. These results were shared in an oral presentation today at the 27th European Academy of Dermatology and Venerology (EADV) Congress in Paris, France.
“The positive results of this Phase 2 study demonstrate the potential of ruxolitinib cream to offer a novel, effective non-steroidal topical therapy to the millions of patients suffering from AD,” said Steven Stein, M.D., Chief Medical Officer, Incyte. “We look forward to further advancing the True-AD clinical trial program for ruxolitinib cream and initiating Phase 3 registrational trials in this indication to further explore the potential of JAK inhibition to modulate inflammation and itch, and therefore provide much-needed relief to patients with this disease.”
Key study results included:
- Significantly improved EASI score in the ruxolitinib cream 1.5% BID arm versus vehicle at Week 4 (71.6 percent vs. 15.5 percent improvement; P<0.001), the primary endpoint, and improvement (meeting the criteria for non-inferiority) in EASI score versus the active control, triamcinolone 0.1% cream (a mid-potency topical corticosteroid), at Week 4 (71.6 percent vs. 59.8 percent improvement), a secondary endpoint.
- Significantly improved EASI scores in the ruxolitinib cream 1.5% BID arm versus vehicle at Weeks 2 and 8 (52.7 percent vs. 4.8 percent and 78.5 percent vs. 26.9 percent, respectively; P<0.001).
- Significantly greater changes in EASI score in the once daily (QD) ruxolitinib cream 1.5% and 0.5% arms versus vehicle at Week 4 (1.5% QD [67.0 percent vs. 15.5 percent improvement], 0.5% QD [52.2 percent vs. 15.5 percent improvement]; P<0.001).
- Significantly more Investigator’s Global Assessment (IGA) responders – a measure of disease severity – in the ruxolitinib cream 1.5% BID arm versus vehicle at Week 4 (38.0 percent vs. 7.7 percent; P<0.001), and greater IGA response rates across other ruxolitinib arms versus vehicle.
- Rapid and sustained reductions in itch numerical rating scale (NRS) score observed as early as within two days from the initiation of therapy (ruxolitinib cream 1.5% cream BID vs. vehicle, ‒1.8 vs. ‒0.2; P<0.0001), and a more pronounced reduction in itch with ruxolitinib cream 1.5% BID and QD than with triamcinolone cream 0.1% BID.
Ruxolitinib cream was well-tolerated at all dosage strengths and was not associated with clinically-significant application site reactions. All treatment-related adverse events were Grade 1 or Grade 2 in severity.
Ruxolitinib cream is the first JAK1/JAK2 inhibitor to exhibit positive results as a topical monotherapy in the AD patient population. Over-activity of the JAK signaling pathway has been shown to drive inflammation involved in the pathogenesis of AD. These data support the planned initiation of a global, pivotal Phase 3 program, for which preparations are already underway.
"There is no cure for AD, and it continues to be a major therapeutic challenge for patients, primary care providers and specialists. Though topical corticosteroids have been a mainstay in treatment of AD for decades, their utility has been limited due to significant side effects associated with long-term use,” said principal investigator of the trial, Brian Kim, M.D., M.T.R., F.A.A.D., Assistant Professor of Dermatology and Co-Director of the Center for the Study of Itch at Washington University School of Medicine in St. Louis, Missouri, USA. “There is an urgent need for new and innovative treatments for patients with this condition, which tends to be chronic. As a physician who treats patients with AD, I am encouraged by the potential of ruxolitinib cream to fill this gap.”
About Atopic Dermatitis
Atopic dermatitis (AD) is a common chronic disease characterized by inflammation of the skin. Approximately 11 million people in the United States have been diagnosed with AD, and the majority (10 million) have a mild or moderate form of the disease. Signs and symptoms of AD include skin rash and dry skin, and it can cause intense itching, scratching and lesions that may ooze or crust. Patients with AD are also more susceptible to bacterial, viral and fungal infections.
About the Study
The safety and efficacy of ruxolitinib cream in adults with atopic dermatitis (AD) were evaluated in an Incyte-sponsored randomized, dose-ranging, vehicle- and active- controlled Phase 2b study (NCT03011892), which began in December 2016 and completed in March 2018. The study, part of the True-AD clinical trial program, enrolled 307 adults (aged 18-70 years) diagnosed with AD for at least two years and who were candidates for topical therapy.
Patients with AD on 3 to 20 percent of their body surface area, with an IGA score of 2 to 3, were equally randomized across six treatment-arms, including: twice daily (BID) ruxolitinib 1.5% cream; once daily (QD) ruxolitinib 0.15%, 0.5% or 1.5% cream; vehicle (non-medicated cream); and active control (triamcinolone 0.1% cream [TAC], a mid-potency topical corticosteroid). All patients received eight weeks of blinded study treatment; the TAC arm received four weeks of TAC followed by four weeks of vehicle; and there was an additional four weeks of open-label ruxolitinib 1.5% cream BID.
The primary efficacy endpoint was mean percentage change from baseline in Eczema Area and Severity Index (EASI score) – a measurement of the extent and severity of AD – at Week 4 in the ruxolitinib 1.5% BID arm versus vehicle. Key secondary endpoints included percent change from baseline in EASI score at Week 4 in the other ruxolitinib cream arms versus vehicle BID and versus triamcinolone 0.1% cream; the proportion of patients achieving an IGA score of 0 (clear) to 1 (almost clear) with at least a 2-point improvement from baseline; the proportion of patients achieving at least a 75 percent improvement from baseline in EASI (EASI75); itch numerical rating scale (NRS); and safety through 12 weeks of dosing.
For more information about the study, please visit https://clinicaltrials.gov/ct2/show/NCT03011892.
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company's web site at www.incyte.com.
Follow @Incyte on Twitter at https://twitter.com/Incyte.
Except for the historical information set forth herein, the matters set forth in this release contain predictions, estimates and other forward-looking statements, including statements regarding the potential of ruxolitinib cream to meaningfully improve the outcomes of patients with atopic dermatitis and plans to initiate a pivotal study. These forward-looking statements are based on Incyte’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including scheduling and related issues with respect to study initiation, unanticipated developments in and risks related to the efficacy or safety of ruxolitinib cream for the treatment of atopic dermatitis, the results of additional data and additional analyses of data from this study, actions taken by regulatory authorities, and other risks detailed from time to time in Incyte’s reports filed with the Securities and Exchange Commission, including its Form 10-Q for the quarter ended June 30, 2018. Incyte disclaims any intent or obligation to update these forward-looking statements.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Warm welcome for ABB Formula E in Davos19.1.2019 09:00 | Pressemelding
Just a few days before the start of the World Economic Forum 2019, Davos is celebrating a world premiere: The latest ABB FIA Formula E racing car - dubbed Gen2 – was transported on a train from the iconic Swiss Rhaetian Railway to Europe’s highest city, where it will be an exciting eyecatcher during the coming week at the Davos Platz railway station. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190119005003/en/ ABB FIA Formula E racing car in Davos (Photo: Business Wire) From this Saturday until next Sunday, January 27, the Gen2 will be on display in a special glass case. Interested passersby can learn about the ABB FIA Formula E racing series as well as about the activities of ABB in e-mobility via an information system. With over 8,500 fast charging stations installed in 70 countries around the world, ABB is the global market leader for charging infrastructures. To watch the video, click here ABB (ABBN: SIX Swiss Ex) is
PMI’s Mission Winnow Goes Full Throttle with Ducati Corse for 2019 MotoGP™18.1.2019 17:00 | Pressemelding
Philip Morris International Inc. (PMI) (NYSE: PM) is pleased to announce that its Mission Winnow initiative is expanding in 2019 to include the Ducati Corse racing team. Mission Winnow is a PMI-led campaign to raise global awareness of our passion and determination to constantly improve and evolve, as well as highlight the power of science, technology and innovation to build a better future. PMI has partnered with Ducati Corse since 2002 and has extended the relationship for another three years until the end of 2021. As of the start of this year’s MotoGP season, the team will be officially known as Mission Winnow Ducati. Mission Winnow was first launched in October 2018 with Scuderia Ferrari Mission Winnow, which – like Ducati Corse – has a passion for innovation and a relentless drive to improve in the team’s pursuit of victory. Ducati Corse is one of the most inspiring and resilient teams in MotoGP, with a 70-year history in racing. Ducati fans form a passionate community who appreci
IFF’s Frutarom Division Completes Acquisition of 60% of Thailand-based Mighty18.1.2019 12:50 | Pressemelding
Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris:IFF) (TASE:IFF), announced that its Frutarom Division has completed the acquisition of 60% of the share capital of The Mighty CO. LTD. (“Mighty”), a leading savory solutions provider in Thailand, thus continuing its growth strategy in Southeast Asia. Amos Anatot, President of IFF's Frutarom Division, said, “The completion of this deal with Mighty underscores that the Frutarom division will continue on its growth strategy and pursue attractive companies that create new opportunities or build on current capabilities.” Mr. Anatot continued, “And in this case, we are helping to grow our capabilities in savory solutions – already an area of strength for legacy Frutarom, now IFF." Mighty, founded in 1989, develops, produces and markets reaction flavors, with particular expertise in savory solutions. The company’s portfolio includes flavors, seasoning blends, marinades, and specialty functional raw materials f
LTI Q3 FY19: Constant currency revenue growth up 6.1% QoQ and 20.6% YoY; Net Profit jumps 32.8% YoY18.1.2019 12:02 | Pressemelding
Larsen & Toubro Infotech (BSE code: 540005, NSE: LTI), a global technology consulting and digital solutions company, announced its Q3 FY19 results today. In US Dollars: Revenue at USD 346.9 million; growth of 5.6% QoQ and 18.2% YoY Constant Currency Revenue growth of 6.1% QoQ and 20.6% YoY In Indian Rupees: Revenue at Rs 24,729 million; growth of 6.1% QoQ and 31.3% YoY Net Income at Rs 3,755 million; growth of (6.2%) QoQ and 32.8% YoY “We are pleased to deliver another strong quarter with 5.6% QoQ growth in USD revenues. Our broad-based revenue growth, superior margin delivery and steady cash generation in Q3 is a testimony of our focused execution and client centricity. We are also thrilled to welcome Ruletronics to LTI family. Ruletronics enables businesses to transform and evolve digitally by providing innovative BPM and CRM solutions leveraging Pega Platform.” - Sanjay Jalona, Chief Executive Officer & Managing Director, LTI Recent Deal Wins Nets, the leading payments company in th
Schlumberger Announces Full-Year and Fourth-Quarter 2018 Results18.1.2019 12:00 | Pressemelding
Schlumberger Limited (NYSE: SLB) today reported results for full-year 2018 and the fourth quarter of 2018. (Stated in millions, except per share amounts) Full-Year Results Twelve Months Ended Change Dec. 31, 2018 Dec. 31, 2017 Year-on-year Revenue $32,815 $30,440 8% Pretax operating income $4,187 $3,921 7% Pretax operating margin 12.8% 12.9% -12 bps Net income (loss) - GAAP basis $2,138 $(1,505) n/m Net income, excluding charges & credits* $2,261 $2,085 8% Diluted EPS (loss per share) - GAAP basis $1.53 $(1.08) n/m Diluted EPS, excluding charges and credits* $1.62 $1.50 8% Full-Year Consolidated Revenue by Area North America $11,984 $9,487 26% Latin America 3,745 3,976 -6% Europe/CIS/Africa 7,158 7,072 1% Middle East & Asia 9,543 9,394 2% Other 385 511 n/m $32,815 $30,440 8% North America revenue $11,984 $9,487 26% International revenue $20,446 $20,442 - North America revenue, excluding Cameron $9,668 $7,518 29% International revenue, excluding Cameron $17,675 $17,423 1% *These are non
FLIR Systems Awarded $89 Million Contract from French Armed Forces to Deliver Black Hornet Personal Reconnaissance System18.1.2019 11:00 | Pressemelding
FLIR Systems, Inc. (NASDAQ: FLIR) announced today it has been awarded a contract from the French Defense Procurement Agency (DGA) in support of the French Operational Pocket Drone (DrOP) program. The contract has a ceiling value of $89 million to provide the FLIR Black Hornet® 3 nano-unmanned aerial vehicle (UAV) and Personal Reconnaissance System (PRS) to support French Armed Forces operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190118005085/en/ The French Armed Forces awarded FLIR Systems a contract to deliver the Black Hornet Personal Reconnaissance System for military operations. (Photo: Business Wire) The Black Hornet PRS is the world’s smallest combat-proven nano-Unmanned Aerial System (UAS) and is currently deployed in more than 30 countries. The Black Hornet enables the warfighter to maintain situational awareness, threat detection, and surveillance no matter where the mission takes them. Equipped with el